Joining this wonderful webinar, Francesco Passiglia, MD, Thoracic Oncologist and Associate Professor of Medical Oncology. University of Turin.
Targeted, cancer genomic profile guided cancer therapy is improving patients’ outcomes. It has been proven, that patients treated in first-line based on their genomic profile have a 22% higher probability of survival two years from diagnosis1. And as the number of biomarkers associated with targeted treatments keeps increasing (it is expected to be 21 just in NSCLC already in 20252), there is more hope for cancer patients.
However, according to real-world data analyses of clinical gaps in NSCLC patient management, Turn Around Time (TAT) to complete actionable biomarker result is one of the main barriers to access of patients to precision oncology treatments, especially in NSCLC3.
In this webinar, Francesco Passiglia, MD, Associate Professor of Medical Oncology. University of Turin will summarize the complex landscape of the NSCLC precision oncology biomarkers and treatments and share, how in their hospital they are addressing this barrier with the help of in house rapid NGS, which delivers them complete actionable results as fast as in 3 days, and enables them to make the best informed therapy decisions more timely.
This webinar is sponsored by Thermo Fisher.
